Your browser doesn't support javascript.
loading
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
Du, Ruoxin; Zhang, Xiangmei; Lu, Xiyan; Ma, Xiangmin; Guo, Xinyan; Shi, Chao; Ren, Xiaofei; Ma, Xindi; He, Yutong; Gao, Yuan; Liu, Yunjiang.
Afiliação
  • Du R; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China.
  • Zhang X; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China; Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China.
  • Lu X; Outpatient Department of the Second Affiliated Hospital of the Fourth Military Medical University, Xi'an 710032, China.
  • Ma X; Department of Breast Surgery, Handan Central Hospital, Handan City 056000, China; Research Centre, The Fourth Hospital of Hebei Medical University, China.
  • Guo X; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
  • Shi C; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China; Department of Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China.
  • Ren X; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China; Department of Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China.
  • Ma X; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China; Department of Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China.
  • He Y; Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China.
  • Gao Y; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. Electronic address: gaoyuan321@fmmu.edu.cn.
  • Liu Y; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang City 050017, China; Department of Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang City 050011, China. Electronic address: lyj818326@hebmu.edu.cn.
Drug Resist Updat ; 68: 100947, 2023 05.
Article em En | MEDLINE | ID: mdl-36812747
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fibroblastos Associados a Câncer Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Drug Resist Updat Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fibroblastos Associados a Câncer Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Drug Resist Updat Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China